Analyzing INVO Fertility (NASDAQ:IVF) & Aveanna Healthcare (NASDAQ:AVAH)
by Teresa Graham · The Cerbat GemINVO Fertility (NASDAQ:IVF – Get Free Report) and Aveanna Healthcare (NASDAQ:AVAH – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.
Profitability
This table compares INVO Fertility and Aveanna Healthcare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| INVO Fertility | -116.29% | -85.54% | -31.05% |
| Aveanna Healthcare | 10.56% | 80.70% | 7.42% |
Volatility and Risk
INVO Fertility has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500. Comparatively, Aveanna Healthcare has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for INVO Fertility and Aveanna Healthcare, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| INVO Fertility | 1 | 0 | 0 | 1 | 2.50 |
| Aveanna Healthcare | 0 | 4 | 6 | 1 | 2.73 |
INVO Fertility presently has a consensus target price of $320.00, indicating a potential upside of 17,386.34%. Aveanna Healthcare has a consensus target price of $14.25, indicating a potential upside of 8.61%. Given INVO Fertility’s higher possible upside, analysts plainly believe INVO Fertility is more favorable than Aveanna Healthcare.
Insider and Institutional Ownership
12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are held by institutional investors. 0.4% of INVO Fertility shares are held by insiders. Comparatively, 5.3% of Aveanna Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares INVO Fertility and Aveanna Healthcare”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| INVO Fertility | $6.84 million | 0.67 | -$25.13 million | ($33.83) | -0.05 |
| Aveanna Healthcare | $2.43 billion | 1.18 | $225.03 million | $1.23 | 10.67 |
Aveanna Healthcare has higher revenue and earnings than INVO Fertility. INVO Fertility is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.
Summary
Aveanna Healthcare beats INVO Fertility on 11 of the 13 factors compared between the two stocks.
About INVO Fertility
INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.
About Aveanna Healthcare
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers PDN services, which include in-home skilled nursing services to medically fragile children and adults; nursing services in school settings in which its caregivers accompany patients to school; services to patients in its pediatric day healthcare centers; and employer of record support and personal care services, as well as in-clinic and home-based therapy services, such as physical, occupational, and speech services. The HHH segment provides home health services, including in-home skilled nursing services; physical, occupational, and speech therapy services; and medical social and aide services, as well as hospice services for patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The MS segment offers enteral nutrition supplies and other products, including formulas, supplies, and pumps to adults and children delivered on a periodic or as-needed basis. The company was incorporated in 2016 and is headquartered in Atlanta, Georgia.